Consensus Compass Therapeutics, Inc. OTC Markets
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.550 USD | -10.80% |
|
+32.67% | - |
| 06-29 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark | CI |
| 06-28 | Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000 Growth Benchmark | CI |
Evolution of the Average Target: Compass Therapeutics, Inc.
Evolution of the Target Price: Compass Therapeutics, Inc.
Changes in Analyst Recommendations: Compass Therapeutics, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | ||
| +19.92% | |||||
| +20.09% | |||||
| +31.37% | |||||
| +93.3% | |||||
| +24.59% | |||||
| +29.72% | |||||
| +17.9% | |||||
| -6.97% | |||||
| +4.71% | |||||
| Average | +26.07% | |||||
| Weighted average by Cap. | +26.56% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Raymond James | |
| Wedbush | |
| William Blair & Co. | |
| Cantor Fitzgerald | |
| Canaccord Genuity | |
| Leerink Partners | |
| Guggenheim | |
| Piper Sandler | |
| Ladenburg Thalmann | |
| Jefferies & Co. | |
| Stifel Nicolaus | |
| EF Hutton | |
| HC Wainwright | |
| SVB Leerink | |
| B. Riley | |
| Roth Capital Partners |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CMPX Stock
- CMPX Stock
- Consensus Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
